{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "20345196",
  "DateCompleted": {
    "Year": "2010",
    "Month": "06",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.3109/15360280903583081"
    ],
    "Journal": {
      "ISSN": "1536-0539",
      "JournalIssue": {
        "Volume": "24",
        "Issue": "1",
        "PubDate": {
          "Year": "2010",
          "Month": "Mar"
        }
      },
      "Title": "Journal of pain & palliative care pharmacotherapy",
      "ISOAbbreviation": "J Pain Palliat Care Pharmacother"
    },
    "ArticleTitle": "Hospice and heart disease: missed opportunities.",
    "Pagination": {
      "StartPage": "23",
      "EndPage": "26",
      "MedlinePgn": "23-6"
    },
    "Abstract": {
      "AbstractText": [
        "A relatively low percentage of eligible heart disease patients receive hospice care in the United States. In 2005, the most recent year with complete reporting, only 18.36% of patients who were dying of heart failure and were hospice eligible actually received hospice care. Reasons for this include the lack of reliable prognostic indicators, the lack of a consensus on when to stop life prolonging therapies, and the relatively high cost of life-prolonging (versus life-enhancing) pharmacotherapy such as dobutamine. In addition, most studies and case reports that address symptom management in hospice care focus on cancer patients, not those with nononcologic diagnoses. This lack of evidence may discourage practitioners who care for cardiac patients from referral to hospice programs, and may keep some hospice practitioners from aggressively targeting this population. Strategies to increase hospice program utilization by heart disease patients are discussed."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "ExcelleRx 1601 Cherry Street, Philadelphia, PA 19102, USA. jberry@excellerx.com"
          }
        ],
        "LastName": "Berry",
        "ForeName": "Joni I",
        "Initials": "JI"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Pain Palliat Care Pharmacother",
    "NlmUniqueID": "101125608",
    "ISSNLinking": "1536-0288"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Biomarkers"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Health Services Accessibility"
    },
    {
      "QualifierName": [
        "metabolism",
        "therapy"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Hospice Care"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Palliative Care"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    }
  ]
}